Literature DB >> 19912290

Inflammatory bowel disease: a systematic review on the value of diagnostic testing in primary care.

P Jellema1, M W van Tulder, H E van der Horst, J Florie, C J Mulder, D A W M van der Windt.   

Abstract

AIM: The clinical presentation of inflammatory bowel disease in primary care represents a diagnostic challenge as its symptoms are heterogeneous and common. To assist the primary care physician, we have summarized the available evidence on diagnostic tests in patients with abdominal symptoms.
METHOD: We searched PubMed and Embase and screened references. Studies were selected if the design was a primary diagnostic study. Patients were adults attending with nonacute abdominal symptoms. Tests included clinical assessment, blood or faecal tests or abdominal ultrasonography. Quality assessment using a modified version of the QUADAS tool and data extraction was performed by two reviewers independently. Diagnostic two-by-two tables and pooled estimates of sensitivity and specificity are given. We refrained from pooling when there was considerable clinical or statistical heterogeneity.
RESULTS: A total of 24 studies were included. While the diagnostic performance of the individual symptoms was highly variable (range sensitivity 0.0-0.96, specificity 0.09-1.0), the performance of symptom-based classification systems was both more consistent and better (sensitivity 0.65-1.0, specificity 0.17-0.82). Among faecal and blood tests, calprotectin was studied most frequently and showed the best results (sensitivity 0.61-1.0, specificity 0.71-1.0). Statistical pooling for ultrasonography resulted in a sensitivity of 0.73 (0.65-0.80) and a specificity of 0.95 (0.91-0.97).
CONCLUSION: Although calprotectin and ultrasonography showed consistent and promising findings, none of the studies was performed in primary care. To assist primary care physicians in diagnostic decision making, we urgently need high quality studies performed in primary care.
© 2011 The Authors. Colorectal Disease © 2011 The Association of Coloproctology of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 19912290     DOI: 10.1111/j.1463-1318.2009.02131.x

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  11 in total

1.  Diagnostic Accuracy of Fecal Calprotectin for Pediatric Inflammatory Bowel Disease in Primary Care: A Prospective Cohort Study.

Authors:  Gea A Holtman; Yvonne Lisman-van Leeuwen; Boudewijn J Kollen; Obbe F Norbruis; Johanna C Escher; Angelika Kindermann; Yolanda B de Rijke; Patrick F van Rheenen; Marjolein Y Berger
Journal:  Ann Fam Med       Date:  2016-09       Impact factor: 5.166

Review 2.  Fecal calprotectin use in inflammatory bowel disease and beyond: A mini-review.

Authors:  Bashaar Alibrahim; Mohammed I Aljasser; Baljinder Salh
Journal:  Can J Gastroenterol Hepatol       Date:  2015-04

Review 3.  Practical guidance on the use of faecal calprotectin.

Authors:  Matthew J Brookes; Simon Whitehead; Daniel R Gaya; Antony Barney Hawthorne
Journal:  Frontline Gastroenterol       Date:  2017-02-22

4.  High negative predictive value of a normal faecal calprotectin in patients with symptomatic intestinal disease.

Authors:  James Turvill
Journal:  Frontline Gastroenterol       Date:  2011-09-19

Review 5.  Colorectal cancer diagnosis: Pitfalls and opportunities.

Authors:  Pablo Vega; Fátima Valentín; Joaquín Cubiella
Journal:  World J Gastrointest Oncol       Date:  2015-12-15

6.  The Association of Introducing a Faecal Calprotectin Testing Pathway for Suspected Inflammatory Bowel Disease in Primary Care and Time to Diagnosis or Treatment.

Authors:  Amy Hicks; P John Hamlin; Christian P Selinger
Journal:  Inflamm Intest Dis       Date:  2020-09-09

7.  Utility of faecal calprotectin in inflammatory bowel disease (IBD): what cut-offs should we apply?

Authors:  A Dhaliwal; Z Zeino; C Tomkins; M Cheung; C Nwokolo; S Smith; C Harmston; R P Arasaradnam
Journal:  Frontline Gastroenterol       Date:  2014-03-17

8.  Evaluation of the clinical and cost-effectiveness of the York Faecal Calprotectin Care Pathway.

Authors:  James Turvill; Daniel Turnock; Hayden Holmes; Alison Jones; Eleanor Mclaughlan; Victoria Hilton; Stacey Marriott
Journal:  Frontline Gastroenterol       Date:  2018-06-07

9.  Challenges in diagnostic accuracy studies in primary care: the fecal calprotectin example.

Authors:  Gea A Holtman; Yvonne Lisman-van Leeuwen; Boudewijn J Kollen; Johanna C Escher; Angelika Kindermann; Patrick F van Rheenen; Marjolein Y Berger
Journal:  BMC Fam Pract       Date:  2013-11-25       Impact factor: 2.497

10.  Is there an added value of faecal calprotectin and haemoglobin in the diagnostic work-up for primary care patients suspected of significant colorectal disease? A cross-sectional diagnostic study.

Authors:  Sjoerd G Elias; Liselotte Kok; Niek J de Wit; Ben J M Witteman; Jelle G Goedhard; Mariëlle J L Romberg-Camps; Jean W M Muris; Karel G M Moons
Journal:  BMC Med       Date:  2016-09-26       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.